Overcast 55°
Tag:

Pfizer/BioNTech

News
COVID-19: New Data Reveals How Many Americans Have Gotten Updated Vaccine Shots COVID-19: New Data Reveals How Many Americans Have Gotten Updated Vaccine Shots
Covid-19: New Data Reveals How Many Americans Have Gotten Updated Vaccine Shots New data is shedding light on how many Americans have received a dose of the new COVID-19 booster shot for 2023-24. The updated vaccine has now been available for about a month and a half. More than 1,200 people are dying of COVID each week in the United States  four years after the pandemic started, the CDC says. The Centers for Disease Control and Prevention (CDC) recommended the newest vaccine targeting Omicron subvariants being provided by both Pfizer/BioNTech and Moderna for everyone 6 months of age and older. Another updated vaccine, this one from Novavax, b…

SHARE

by Joe Lombardi
News
COVID-19: Here's How Many Americans Have Gotten Updated Vaccine Compared To Last Year's Booster COVID-19: Here's How Many Americans Have Gotten Updated Vaccine Compared To Last Year's Booster
Covid-19: Here's How Many Americans Have Gotten Updated Vaccine Compared To Last Year's Booster More than seven million Americans have received a dose of the newly released COVID-19 booster shot for 2023-24, according to federal authorities. In mid-September, the Centers for Disease Control and Prevention (CDC) recommended the newest vaccine targeting Omicron subvariants being provided by both Pfizer/BioNTech and Moderna for everyone 6 months of age and older. Another updated vaccine, this one from Novavax, became available this month and is recommended for those aged 12 and over.  The rollout of this year's booster was marked early on by some distribution of…

SHARE

by Joe Lombardi
News
COVID-19: FDA Panel Recommends Booster Shots For Some Americans COVID-19: FDA Panel Recommends Booster Shots For Some Americans
Covid-19: FDA Panel Recommends Booster Shots For Some Americans COVID-19 vaccination booster shots are now being recommended for some Americans, but not others, a federal advisory group just announced. The Food and Drug Administration's scientific advisory committee held daylong discussions on Friday, Sept. 17 after which it determined that those who are age 65 or older or are at high risk of severe COVID should get booster shots. Earlier, the panel announced it had overwhelmingly voted against approving a Pfizer/BioNTech booster for all people 16 and older. The vote was 16-2. The FDA typically follows the determinations of the panel. A group of …

SHARE

by Joe Lombardi
News
COVID-19: FDA Grants Full Approval For Pfizer Vaccines, With More Mandates Now Expected COVID-19: FDA Grants Full Approval For Pfizer Vaccines, With More Mandates Now Expected
Covid-19: FDA Grants Full Approval For Pfizer Vaccines, With More Mandates Now Expected The US Food and Drug Administration (FDA) has granted full approval to the Pfizer/BioNTech COVID-19 vaccine for anyone 16 and older. On Monday, Aug. 23, the FDA announced that the Pfizer vaccine has been granted full approval, which is expected to potentially open the door for more COVID-19 vaccine mandates. The Pentagon will mandate vaccines for its 1.4 million active-duty service members, following the FDA approval Monday. United Airlines recently said its employees will be required to show proof of vaccination within five weeks of regulatory approval.  Pfizer is the first COVID-1…

SHARE

by Zak Failla
News
COVID-19: Here's How Many Have Missed Scheduled Second Dose Of Vaccine So Far, CDC Says COVID-19: Here's How Many Have Missed Scheduled Second Dose Of Vaccine So Far, CDC Says
Covid-19: Here's How Many Have Missed Scheduled Second Dose Of Vaccine So Far, CDC Says A larger number of Americans are skipping their scheduled second shot for the COVID-19 vaccine, according to new data released from the US Centers for Disease Control and Prevention. The CDC found that most recently, more than five million people, approximately 8 percent of those receiving vaccines from Moderna and Pfizer/BioNTech - which require two doses several weeks apart to complete the process - have skipped their second doses. That number is up from approximately 3.4 percent a month ago as the country was ramping up its vaccination program. Officials noted that the CDC is still coll…

SHARE

by Zak Failla
News
COVID-19: Pfizer Will Seek Vaccine Rollout For Younger Teens After Encouraging Trial Results COVID-19: Pfizer Will Seek Vaccine Rollout For Younger Teens After Encouraging Trial Results
Covid-19: Pfizer Will Seek Vaccine Rollout For Younger Teens After Encouraging Trial Results Clinical trials of the Pfizer/BioNTech’s COVID-19 vaccine showed that it has a 100 percent efficacy in adolescents and is well-tolerated in minors between the ages of 12 and 15, paving the way for distribution, the companies announced. Officials said that initial trials were fruitful, and they plan to submit the data to the U.S. Food and Drug Administration for expanded emergency use authorization of the two-dose vaccine in adolescents. According to Pfizer, the third phase of the clinical trial included 2,260 participants between the ages of 12 and 15, which found that strong antibody respo…

SHARE

by Zak Failla
News
COVID-19: Cases Of More Contagious South African Strain Have Now Been Reported In These States COVID-19: Cases Of More Contagious South African Strain Have Now Been Reported In These States
Covid-19: Cases Of More Contagious South African Strain Have Now Been Reported In These States The more transmittable COVID-19 variant from South Africa continues to make the rounds across the country, with newly confirmed cases of the strain being reported throughout the Northeast. The South African COVID-19 strain has now been reported in nine states, including New York, Connecticut, and Massachusetts, and one territory, as the country works to vaccinate as many people as possible to prevent the spread of the virus. Other states reporting confirmed cases of the South African strain include: California; Texas; Illinois; Virginia; South Carolina; Maryland; The District of Col…

SHARE

by Zak Failla